Credit: Skin and Cancer Associates and The Center for Cosmetic Enhancement

The number of innovative approaches to an array of both common and uncommon dermatologic diseases has grown in recent years, and many dermatologists have sought to share clinical pearls related to these approaches with other clinicians in the field.

2026 American Academy of Dermatology (AAD) Annual Meeting

 in Denver, a session on these topics titled ‘Pearls: Diagnostic and Therapeutic’ was given by several notable speakers, 1 of whom was Brad P. Glick, DO, MPH, a board-certified dermatologist and the director of the dermatology residency training program at the Larkin Health System Palm Springs campus in Florida.

 editorial team about his portion of this session, describing several key insights on treating conditions appearing on patients’ nails, designed to help dermatology clinicians:

 Your portion of this session on diagnostic and therapeutic pearls covers nail disease within dermatology. Why did you feel the topic was important to pursue?

In our training in dermatology, I think one of the areas that doesn't necessarily get a ton of attention. While I didn't necessarily talk about a particular publication, because there are publications on this topic, I don't think nails get a lot of attention on our training. [This is] because there's just so much else going on. We have to learn about the basement membrane zone, then we apply that clinically to blistering diseases and immune mediated skin diseases. So we learn about how it treats psoriasis and eczema and lichen planus and this multitude of over 3000 diseases that we take care of in dermatology that I think probably the nails get a little neglected.

Deborah Lin, who is a resident University of Miami under the tutelage of Dr. Brian Morris, and her residency program director, a couple of years ago, published a really nice paper just vetting this, [noting] that even in programs where they have nail knowledge…our dermatology residents coming out of training and, if there's an area where they maybe feel a little bit uncomfortable, it's with nails. [This is] not only with assessment, but also with just how to do a biopsy, where to look, how to assess. So I think that was one of the main reasons why I like to provide tips.

Most of my tips are literature based, whether this relates to various topics like, let's say, the impact of biologic therapies and systemic therapies on nail diseases, whether it relates to the technique of doing an intra-lesional injection, and what that actually means. Where you're doing the injection depends largely on how you assess the nail. So those were the primary reasons, because I think we need more in our residency training programs.

Would you highlight some of the biggest takeaways that you mentioned within the session?

I think that one of the things that I talked about was the use of systemic small molecules and biologic therapies in the treatment of psoriatic disease, specifically psoriasis. You know, one of the things I highlighted is that when we're evaluating patients who have psoriatic disease, we really need to look at, first and foremost, as confirmed by some of the recent international psoriasis Council and AAD guidelines, high impact areas. The nails are critically important. So I think, as I tell my residents, if someone's there for psoriasis and their shoes and socks are still on, they need to take them off. They always need to look at all 20 nail units, because patients with nail psoriasis are three to four times more likely to develop psoriatic arthritis compared to those that really don't have nail changes associated with their psoriasis. 

I think that's important, because in addition to seeing that, we also need to be screening our patients for psoriatic arthritis. Of course, we do a test called the PEST test, which is the psoriasis epidemiology screening tool, and it's all intertwined. One of the things I talked about is not only assessing the nails in the setting of an immune mediated skin disease like psoriasis…but also, there is significant impact by a number of our biologic therapies on psoriatic nail disease. So I think a we need to hone in on that assess accordingly, not just look at it from the standpoint of making the nails look or feel better, because a lot of times we don't ask, and a lot of our patients with nail changes in psoriatic disease.

They're uncomfortable, they have mechanical issues. It impacts their quality of life, but moreover, they may be one of those 30% of individuals who actually may either have or move on to develop psoriatic arthritis. I think rapid assessment is important, and realizing that we have specific biologic therapies that hadn't been studied directly for nail diseases, including tumor necrosis factor inhibitors, which are older therapies now they're mostly biosimilars…There are other post hoc analyses from our more modern day IL-17 and IL-23 inhibitors that demonstrate not only improvement in nail disease, but perhaps we are either pre-treating or treating their active psoriatic arthritis. That was really one very important area of discussion that I discussed in my my presentations on nail tips and tricks.

One of the things I also did for the audience was spend maybe 15 of my 30 minutes just going over nail terminology and different nail findings, because they are either common signs of normal health or aging, or they may be visible markers for systemic disease. I talked a lot about nail signs in general, not specific references to literature, although I did that in my remaining time, because there are some key journal articles that have been published just in the last year that I think are critical for us in our assessments for patients with nail diseases. I did talk a lot about nail terminology and nail signs of systemic disease. One other thing that I also talked about that I thought was important, because there are some new, if you will, data or information on how we assess certain nail signs of systemic disease, and one of them is the yellow nail syndrome.

Yellow nail syndrome is not particularly common, but on the other hand, it is a potential skin sign of systemic disease, where all 20 nails take on a yellow or sometimes a yellowish green color. And one of the hallmarks the presentation of patients who have yellow nail syndrome are complete absence of their cuticles. It's very, very unique presentation. And there's a wide differential diagnosis. It can look like fungus…But what's important about this particular condition is that it involves all 20 nails. Typically, the patients will present with a yellow discoloration, or yellow green discoloration of their nails. It's important to recognize this because it may be a nail sign of systemic problem, like cardiovascular disease, pulmonary disease, and more important malignancies such as bronchogenic carcinoma.

The quotes used in this Q&A interview summary were edited for clarity.

Glick had no relevant disclosures to highlight for this session.

Glick B, et al. S005 Pearls: Diagnostic and Therapeutic. Session presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.

Lee DK, Lipner SR. Optimal diagnosis and management of common nail disorders. Ann Med. 2022 Dec;54(1):694-712. doi: 10.1080/07853890.2022.2044511. PMID: 35238267; PMCID: PMC8896184.

Articles

Nail pathology remains underemphasized in dermatology training despite its diagnostic value and procedural complexity. Focused assessment of all 20 nail units is essential in psoriasis, given nail involvement’s association with increased psoriatic arthritis risk and meaningful quality-of-life impairment. Contemporary systemic agents, including IL-17 and IL-23 inhibitors, show post hoc benefits for nail disease and may address concomitant joint activity. Standardized nail terminology and pattern recognition can distinguish aging-related changes from systemic markers. Yellow nail syndrome, characterized by diffuse discoloration and absent cuticles, warrants evaluation for cardiopulmonary disease and malignancy.

This Q&A interview at AAD 2026 highlights a number of notable tips for clinicians in dermatology from the ‘Pearls: Diagnostic and Therapeutic’ talk.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Key Diagnostic and Therapeutic Pearls in Dermatology, With Brad P. Glick, DO, MPH

Chelsea Christensen, PA-C, is a cardiology physician assistant at Sentara Virginia Beach General Hospital.

ZOLL Heart Failure Management System Predicts Events Before Hospitalization, With Chelsea Christensen, PA-C

The ZOLL Heart Failure Management System (HFMS) has demonstrated efficacy in the clinic by predicting and warning clinicians and patients of 

 events before they occur, avoiding hospitalizations.

American College of Cardiology (ACC) Scientific Sessions 2026

 editorial team spoke with Chelsea Christensen, PA-C, a cardiology physician assistant at Sentara Virginia Beach General Hospital, to discuss her experience with the ZOLL HFMS device.

“A lot of times, patients are frustrated – they’re back in the hospital for the third, fourth, even fifth time," Christensen told 

 in an exclusive interview. “It’s been really interesting to use the HFMS device and catch this fluid before the patients even know that it’s coming back.”

The ZOLL HFMS system is a wearable patch that utilizes radiofrequency to detect changes in pulmonary fluid levels early. Radar waves propagate through the lungs to measure interstitial edema – changes in the signal path delay or strength indicate changes in fluid presence. Additionally, the waves are highly modulated by tissue hydration, generating a sensitive and robust measurement named the Thoracic Fluid Index (TFI). Proprietary algorithms then determine patient-specific changes in pulmonary fluid before symptoms begin.

The ZOLL HFMS first received clearance from the US Food and Drug Administration (FDA) in 2019. This decision was made following positive data from a multicenter, multinational, prospective, concurrent-control clinical trial composed of 2 arms – Benefit of Microcor in Ambulatory Decompensated Heart Failure (control arm) (BMAD-HF), and Benefit of Microcor in Ambulatory Decompensated Heart Failure (intervention arm) (BMAD-TX). The study was powered for a primary endpoint of the comparison of HF hospitalization by time to first event between the 2 arms.

Patients were eligible for inclusion in BMAD-HF or BMAD-TX if they had been discharged from the hospital for HF in the previous 10 days and had an HF event within the previous 6 months, which was defined as a hospitalization, emergency department visit, or an unplanned clinical visit. Patients with wearable cardiac defibrillators, subcutaneous implantable cardioverter-defibrillators, or those who had a life expectancy of <1 year due to noncardiac diseases, among other criteria, were excluded.

Patients were asked to wear the HFMS continuously for ≤90 days with the option to extend to ≤180 days. They were required to fill out a diary throughout the study, recording any HF symptoms/events or medication changes. Additionally, all patients received standard-of-care management, participating in weekly phone calls and monthly office visits to collect HF symptom and event information.

In the control arm, both patients and investigators were blinded to the device data; in the intervention arm, device data was shared with the investigators, who could then share reviewed data with patients in the study. The impact of HF management with the HFMS was evaluated using Kaplan-Meier analysis of the time to first HF hospitalization for each patient.

A total of 522 patients were enrolled across 93 sites – of these, 245 subjects in BMAD-HF and 249 in BMAD-TX were eligible for intention-to-treat analysis. By the 90-day marker, 108 hospitalizations occurred in 82 patients. Based on these data, investigators determined that patients in the arm managed using HFMS data to direct HF therapy exhibited a 38% lower HF hospitalization rate during the 90 days following an HF hospitalization versus the control arm (HR, 0.62; 

 = .03), with an absolute reduction of 7%.

Christensen also discussed her clinic’s plans to expand the use of the HFMS to a broader patient cohort, as well as larger-scale plans for accessibility.

“I think there are definitely ways to expand it, and that’s where we’re at in my program right now,” Christensen said. “But it’s all about getting bigger, because we’ve seen such great results with it. The name of the game is just making it bigger and trying to make it more accessible to more patients.”

Editors’ Note: Christensen reports no relevant disclosures.

Heart failure management system (HFMS) medical professional overview. ZOLL. Accessed April 10, 2026. 

https://cardiac.zoll.com/medical-professionals/heart-failure-management-system

Boehmer, J, Cremer, S, Abo-Auda, W. et al. Impact of a Novel Wearable Sensor on Heart Failure Rehospitalization: An Open-Label Concurrent-Control Clinical Trial. 

https://doi.org/10.1016/j.jchf.2024.07.022

Videos

Christensen discusses the mechanics and practical applications of the HFMS, emphasizing its success in predicting HF events based on pulmonary fluid levels.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Strategic Alliance Partnership

Tirzepatide Outperforms Dulaglutide in Cardiorenal Outcomes, With Steven Nissen, MD

Tirzepatide treatment resulted in a substantial reduction in a broad 6-component composite of cardiovascular and kidney endpoints compared to dulaglutide, according to a post hoc analysis of the SURPASS-CVOT trial.

 in New Orleans, Louisiana, by Steven Nissen, MD, chief academic officer of the Heart and Vascular Institute at the Cleveland Clinic and professor of medicine at the Lerner College of Medicine.

“What this tells us is that targeting 2 incretins, which is what tirzepatide does, is actually a better strategy in terms of reducing major morbidity and mortality than just targeting GLP-1 alone,” Nissen told 

 in an exclusive interview. “We’re moving beyond the simple GLP-1 agonists – we’re moving to these more complex therapies that involve targeting more than 1 of the gut hormones.”

SURPASS-CVOT was an active-comparator-controlled, double-blind, noninferiority trial comparing tirzepatide and dulaglutide for cardiovascular outcomes in patients with 

atherosclerotic cardiovascular disease (ASCVD)

. Patients were eligible if they were ≥40 years old with T2D, a glycated hemoglobin level between 7% and 10.5%, a body mass index (BMI) of ≥25, and established ASCVD. Patients were excluded if they had any cardiovascular event within 60 days before screening, had used a GLP-1 RA within 3 months before screening, or had chronic advanced 

Eligible patients were randomized in a 1:1 ratio to either weekly subcutaneous tirzepatide 15 mg or dulaglutide 1.5 mg. Patients were monitored at trial visits every 4 weeks for the first 24 weeks and every 3 months thereafter. A total of 6586 patients entered the tirzepatide arm and 6579 entered the dulaglutide arm. The primary endpoint was a composite of cardiovascular mortality, myocardial infarction, or stroke.

Among the 13,165 patients enrolled in the original trial, the mean age was 64 years (standard deviation [SD], 8.8), and mean hemoglobin A1c was 8.4% (SD, 0.93). A primary endpoint event occurred in 801 patients (12.2%) in the tirzepatide arm and 862 (13.1%) in the dulaglutide arm. Adverse event incidence was similar between the 2 groups, although tirzepatide recipients saw more gastrointestinal adverse events.

In the present analysis, Nissen and colleagues crafted an additional primary endpoint composed of 6 potential events, including all-cause mortality, myocardial infarction, stroke, coronary revascularization, hospitalization for heart failure, and a composite of several adverse kidney outcomes.

This 6-point composite endpoint occurred in 1559 patients (23.7%) receiving tirzepatide and 1803 patients (27.4%) receiving dulaglutide (HR, 0.84; 95% CI, 0.79-0.9; 

 <.001) after a median treatment duration of 46.9 months (interquartile range [IQR], 34.6-50.6). Sensitivity analyses showed similar hazard ratios for a 5-component endpoint excluding kidney outcomes (HR, 0.86; 95% CI, 0.8-0.93).

Nissen noted the limited structure of the trial, given its status as a post hoc analysis. Tirzepatide’s explicit superiority in this particular patient cohort cannot be assumed based on these data.

“It’s important to remember that this is a secondary analysis of a trial,” Nissen said. “I happen to be the chair of the study SURMOUNT-MMO, which is studying tirzepatide compared to placebo in both primary and secondary prevention patients without diabetes. We’ll find out in a much broader population whether targeting with a dual incretin therapy really is superior to placebo.”

Editors’ Note: Nissen reports disclosures with Amgen, AstraZeneca, Bristol Myers Squibb, Novartis, Medtronic, Eli Lilly, and others.

Nissen SE, Wolski K, D’Alessio D, et al. Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial. 

. March 28, 2026. Accessed April 10, 2026. 

Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with Tirzepatide versus dulaglutide in type 2 diabetes. 

Nissen discusses his post-hoc analysis of the SURPASS-CVOT trial, comparing the 2 drugs for a 6-component composite endpoint of cardiorenal outcomes.

Atherosclerotic Cardiovascular Disease

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Michael H. Gold, MD, is the founder and medical director of Gold Skin Care Center, Advanced Aesthetics Medical Spa, The Laser & Rejuvenation Center.

How to Deal With Cosmetic Complications in Dermatology, With Michael H. Gold, MD

 practice, cosmetic procedures have become an increasingly central element, with energy-based devices and other aesthetic interventions now being used routinely in a wide array of clinical settings.

However, dermatology clinicians know complications occur, even in the most experienced hands. A session, titled ‘Complications of Cosmetic Procedures,' was presented at the 

 by several speakers, including Michael H. Gold, MD, the founder and medical director of Gold Skin Care Center, Advanced Aesthetics Medical Spa, & The Laser & Rejuvenation Center.

“Everybody will see a complication,” Gold explained. “If you don't, the old adage is you haven't done enough. The issue is understanding that it is a complication early, working with the patient to make sure they understand you know what you're doing, and coming up with a solution that makes it get better fast.”

Gold described complications as not a matter of if, but when. His core message throughout his session was that the ability to recognize a complication early, communicate openly with those involved, and to move quickly toward a solution is what separates a manageable setback from a lasting problem. He described the vast majority of complications are reversible when approached properly.

Throughout his talk, Gold drew on his 35-plus years of experience, sharing a variety of examples from cases in both his own practice and colleagues with whom he runs complication panels throughout the year. Intense pulsed light (IPL) was highlighted as 1 unique focus. Gold described newer machines as having diminished the incidence of burns, blistering, and shifts in pigment, yet he added that the risks have not been eliminated completely.

Additionally, Gold cautioned clinicians in the dermatology space against cutting corners on device quality, describing less expensive machines as often less rigorously assessed. He also touched on the medical-legal dimensions of complication management, noting clinicians should consider informed consent, detailed documentation, and pre-procedure photography as essential.

For any additional information on complications, view the full video interview from AAD 2026 posted above.

The quotes contained in this interview summary were edited for clarity.

Gold reports relationships with multiple companies, including roles as a consultant (honoraria) for Acclaro Medical, Aesthetic Management Partners, Aesthetics Biomedical, Alastin Skincare, Inc., Allergan, Inc., Benev, Galderma, Hugel, InMode, La Mer, Mindera, MTF Biologics, Nutrafol, Pierre Fabre, Prescriber’s Choice, Revision Skincare, Rohrer Aesthetics, Sciton Inc., Sensus Healthcare, Sente Labs, SkinBetter Science, SkinCeuticals LLC, SkinMedica, Inc., Sofwave, Stratapharma, and VIOL. He has served as a speaker (honoraria) for Alma Lasers, Cutera, Inc., EndyMed Medical Inc. USA, Lumenis, Merz Pharmaceuticals, LLC, and Venus Concept. He is an investigator (grants/research funding) for Bausch Health, Leo Pharma Inc., Revance Therapeutics, Inc., Revision Skincare, and SkinBetter Science. He also reports stockholder status with Aerolase and stock options with Venus Concept.

Perez SM, Kennedy DJ, Landau M, et al. Implications of Dermatologic Disorders in Facial Cosmetic Surgery: A Systematic Review. Ann Plast Surg. 2026 May 1;96(5):404-412. doi: 10.1097/SAP.0000000000004731. Epub 2026 Mar 19. PMID: 41848703.

Gold M, et al. S051 Complications of Cosmetic Procedures. Session presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.

During this video interview at AAD 2026, Gold touches on key points made in his session titled ‘Complications of Cosmetic Procedures.’

TETON-2 Supports Antifibrotic Benefit of Inhaled Treprostinil in IPF, With Steven Nathan, MD

Inhaled treprostinil (Tyvaso; United Therapeutics) significantly preserved lung function and reduced the risk of clinical worsening compared with placebo over 52 weeks in patients with idiopathic pulmonary fibrosis (IPF) — findings that Steven D. Nathan, MD, FCCP, argues position the drug as a first inhaled antifibrotic therapy and validate a years-long hypothesis derived from an earlier pulmonary hypertension trial.

Nathan, medical director of the Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital in Falls Church, Virginia, and chair of the TETON steering committee, was the presenting author of the TETON-2 results at the European Respiratory Society meeting in Amsterdam in September 2025., and later the full paper published in the 

spoke with Nathan to learn more about TETON-2, a phase 3, multicenter, randomized, double-blind, placebo-controlled trial enrolling 593 patients with IPF across sites in Asia-Pacific, Europe, and Latin America. Patients in the trial were randomly assigned 1:1 to receive nebulized treprostinil or placebo, titrated from 3 breaths 4 times daily to a target regimen of 12 breaths 4 times daily over 52 weeks. The mean patient age was 71.7 years, 80.1% were men, mean baseline forced vital capacity (FVC) was 76.8% predicted, and 75.4% were receiving background antifibrotic therapy with nintedanib or pirfenidone.

The trial met its primary endpoint: the median change in absolute FVC at week 52 was −49.9 mL (95% CI, −79.2 to −19.5) in the treprostinil group versus −136.4 mL (95% CI, −172.5 to −104.0) in the placebo group, yielding a between-group difference of 95.6 mL (95% CI, 52.2 to 139.0; 

 <.001). Treprostinil also significantly reduced the risk of clinical worsening, with events occurring in 81 patients (27.2%) in the treprostinil group versus 115 (39.0%) in the placebo group (hazard ratio, 0.71; 95% CI, 0.53 to 0.95; 

 = .02), a 29% risk reduction. These benefits were observed across all analyzed subgroups, including patients with and without background antifibrotic therapy, across smoking histories, and in those using supplemental oxygen. No substantial between-group difference in time to acute IPF exacerbation was observed, precluding formal inference on subsequent prespecified secondary endpoints per the hierarchical testing procedure. The most common adverse event was cough, reported in 48.3% of treprostinil-treated patients versus 24.1% of those receiving placebo; the overall safety profile was consistent with prior Tyvaso experience and known prostacyclin-related adverse events, with no new safety signals identified.

Nathan described the conceptual underpinning of the TETON program as originating from an ad hoc analysis of the INCREASE trial — a phase 3 study of inhaled treprostinil in pulmonary hypertension associated with interstitial lung disease (PH-ILD), published in the 

 in March 2021, which supported the drug's approval for that indication. Although FVC was assessed in INCREASE as a safety measure rather than an efficacy endpoint, patients who received inhaled treprostinil demonstrated better lung function at week 16 than those on placebo, and patients who crossed over to open-label treprostinil from placebo showed subsequent FVC gains — a signal Nathan characterized as suggesting independent antifibrotic properties beyond vasodilation. That hypothesis became the foundation for the TETON program, which also includes a third study, TETON-PPF, evaluating inhaled treprostinil in progressive pulmonary fibrosis beyond IPF.

TETON-1, the North American sister study enrolling 598 patients in the United States and Canada, reported positive topline results in March 2026, with treprostinil demonstrating superiority over placebo for absolute FVC change from baseline to week 52 by 130.1 mL (Hodges-Lehmann estimate, 95% CI, 82.2 to 178.1 mL; 

 <.0001) — a treatment effect exceeding that observed in TETON-2. TETON-1 also achieved statistical significance for reducing the risk of clinical worsening. United Therapeutics plans to submit a supplemental New Drug Application to the FDA by the end of summer 2026 seeking to add IPF to the labeled indications for nebulized Tyvaso, with integrated analyses of both TETON studies to be presented at the American Thoracic Society Annual Meeting in Orlando in May 2026.

“In fact, when the placebo arm got converted to open label with treprostinil, the FVCs went up. So this gave us some kind of indication that maybe treprostinil had independent anti fibrotic properties, and that was the foundation and underpinning for the TETON program,” Nathan said.

Nathan’s reported disclosures include AstraZeneca, Avalyn Pharma, Boehringer Ingelheim, Pliant, and United Therapeutics.

Nathan SD, Smith P, Deng C, et al; TETON-2 Trial Investigators. Inhaled treprostinil for idiopathic pulmonary fibrosis. 

. Published online March 11, 2026. doi:10.1056/NEJMoa2512911

United Therapeutics Corporation. United Therapeutics Corporation announces TETON-1 pivotal study of Tyvaso® meets primary endpoint for treatment of idiopathic pulmonary fibrosis, exceeding impressive treatment effect seen in TETON-2. Press release. March 30, 2026. Accessed April 10, 2026. 

https://ir.unither.com/press-releases/2026/03-30-2026-120037465

Treprostinil significantly slowed FVC decline and reduced clinical worsening events over 52 weeks in patients with IPF.


Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Pulmonary Fibrosis

Nicole Chase, MD, is a board-certified allergist/immunologist at St. Paul Allergy Asthma, Minneapolis VA Health Care System (part-time), and an associate professor of medicine at the University of Minnesota Medical School.

Chase discusses how the FDA’s labeling change aligns epinephrine nasal spray (neffy) with other weight-based epinephrine formulations.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Weight-Based Dosing Informs Age Removal for Epinephrine Nasal Spray, With Nicole Chase, MD

Alberico Catapano, PhD, is the research director and head of the laboratory of lipoproteins and atherosclerosis and of the lipid clinic at MultiMedica IRCCS.

Catapano discusses the superior reduction in LDL-C, ApoB, and non-HDL-C demonstrated by enlicitide, suggesting its role as an add-on for LDL-C lowering.

Dyslipidemia

Enlicitide Superior to Oral Non-Statin Therapies for LDL-C Lowering, With Alberico Catapano, PhD

Robert Gish, MD, is the Medical Director of the Hepatitis B Foundation in Doylestown, Pennsylvania. He is an Adjunct Professor of Medicine at the University of Nevada School of Medicine in Las Vegas. He serves as an Adjunct Professor of Pharmacy at Skaggs School of Pharmacy and Pharmaceutical Sciences at UCSD, a Clinical Professor of Medicine at Loma Linda University. In addition, he is the Medical Director of the American Pacific Health Foundation.

In this segment of Liver Lineup, experts discuss genetic testing in cholestatic disease, highlighting real-world cases demonstrating the value of these tests.

Hepatology

Genetic Panels in Hepatology: Identifying the Right Patients

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Experts unpack new T2-targeted biologics for severe asthma and eosinophilic COPD, sharing biomarker tips, sequencing debates and payer hurdles,

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Biologics Across the Airway: Selection, Remission Goals, and Real-World Barriers

Chase explains how the weight-based labeling update for epinephrine nasal spray (neffy) may improve access, adherence, and real-world use in young children.


FDA Removes Age Restriction for Epinephrine Nasal Spray, With Nicole Chase, MD

Anjali Vaidya, MD, is the director of the Advanced Pulmonary Hypertension, Right Heart Failure & CTEPH Program and the Pulmonary Hypertension Fellowship at Temple University Hospital and a professor of medicine at Temple University

Vaidya discusses the 2022 pulmonary arterial hypertension guidelines and how they can be made more accessible for clinicians just entering the field.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

The Mechanics Behind PAH Diagnosis and Management, With Anjali Vaidya, MD

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Hematology

Q1 2026 Recap: Hematology News and Updates

Catch up on nephrology headlines you missed from Q1 2026.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

FDA News

Q1 2026 Recap: Nephrology News and Updates

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Catch up on FDA decisions, new GLP-1 agonists, and more.

Type 1 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Q1 2026 Recap: Endocrinology News and Updates

Expert dermatologists urge aggressive psoriasis control to prevent heart and joint risks, highlight unmet needs, and preview TYK2 inhibitors as a safer oral option.

Latest News

Key Diagnostic and Therapeutic Pearls in Dermatology, With Brad P. Glick, DO, MPH

ZOLL Heart Failure Management System Predicts Events Before Hospitalization, With Chelsea Christensen, PA-C

Tirzepatide Outperforms Dulaglutide in Cardiorenal Outcomes, With Steven Nissen, MD

How to Deal With Cosmetic Complications in Dermatology, With Michael H. Gold, MD

TETON-2 Supports Antifibrotic Benefit of Inhaled Treprostinil in IPF, With Steven Nathan, MD